泽璟制药(688266) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 167,641,962.39, representing a 54.87% increase compared to CNY 108,244,408.58 in the same period last year[3]. - The net profit attributable to shareholders was a loss of CNY 28,262,235.13, an improvement from a loss of CNY 39,499,383.01 year-over-year[3]. - The total operating profit was -30,017,022.32 CNY, an improvement from -45,624,274.29 CNY year-over-year[20]. - The total comprehensive income was -29,173,170.81 CNY, compared to -44,525,871.67 CNY in the previous year, reflecting an improvement of approximately 34.5%[20]. - The net loss for Q1 2025 was ¥17,961,842.86, an improvement from a net loss of ¥31,136,645.78 in Q1 2024, reflecting a reduction in losses by approximately 42.5%[27]. Research and Development - Research and development expenses totaled CNY 102,236,990.94, up 21.21% from CNY 84,346,541.11 in the previous year, accounting for 60.99% of operating revenue, down from 77.92%[4]. - Research and development expenses increased to 102,236,990.94 CNY from 84,346,541.11 CNY, representing a growth of about 21.2%[20]. - Research and development expenses for Q1 2025 were ¥89,598,245.03, an increase of 21.1% compared to ¥73,984,650.89 in Q1 2024[27]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 6,253,152.42, a significant decline of 107.02% compared to a positive CNY 89,023,867.97 in the same period last year[3]. - Cash flow from operating activities was -6,253,152.42 CNY, a significant decline from 89,023,867.97 CNY in the previous year[22]. - The cash and cash equivalents at the end of the period were 152,576,297.68 CNY, down from 1,945,522,532.84 CNY in the previous year[23]. - The company's cash and cash equivalents as of March 31, 2025, amounted to RMB 2,102,866,553.50, a decrease from RMB 2,153,678,920.77 at the end of 2024[14]. - The cash flow from operating activities for Q1 2025 was negative at -¥2,523,956.52, contrasting with a positive cash flow of ¥93,655,601.93 in Q1 2024[29]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,917,823,880.91, a decrease of 2.89% from CNY 3,004,614,283.98 at the end of the previous year[4]. - Total assets as of March 31, 2025, were RMB 2,917,823,880.91, compared to RMB 3,004,614,283.98 at the end of 2024, showing a decrease in total assets[16]. - Total liabilities as of March 31, 2025, were RMB 1,694,094,018.51, down from RMB 1,752,013,734.86 at the end of 2024, indicating a reduction in financial obligations[16]. - The total liabilities decreased to ¥1,663,767,811.52 from ¥1,705,903,359.68, indicating a reduction of approximately 2.5%[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,533[9]. - The top shareholder, Zelin Sheng, holds 49,910,527 shares, representing 18.85% of the total shares[10]. Sales and Revenue - The company reported a significant increase in drug sales, particularly due to the inclusion of thrombin in the national medical insurance catalog, leading to noticeable growth in sales volume[7]. - The company reported a total revenue from sales of goods and services of 193,163,300.70 CNY, an increase from 103,736,772.47 CNY year-over-year[22]. - Total operating revenue for Q1 2025 reached RMB 167,641,962.39, an increase of 55% compared to RMB 108,244,408.58 in Q1 2024[18]. - Total operating costs for Q1 2025 were RMB 224,891,718.58, up from RMB 158,939,244.62 in Q1 2024, reflecting a significant increase in expenses[18]. Other Financial Metrics - The weighted average return on equity was -2.28%, slightly improved from -2.45% in the previous year[3]. - The company's inventory decreased to ¥167,491,327.54 from ¥182,861,135.29, a reduction of approximately 8.4%[25]. - The company's net loss for Q1 2025 was not specified, but the retained earnings showed a negative balance of RMB -2,145,004,719.20 as of March 31, 2025[16]. - Non-recurring gains and losses amounted to CNY 21,818,727.65, primarily driven by government subsidies and other non-operating income[5][6].